Taysha Gene Therapies (TSHA) Accumulated Expenses (2019 - 2026)

Taysha Gene Therapies has reported Accumulated Expenses for 8 years, with the latest figure at $4.9 million in Q1 2026.

• Quarterly Accumulated Expenses rose 93.27% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 93.27% YoY) and the FY2025 annual result came in at $3.6 million, up 109.51% from the prior year.
• Accumulated Expenses climbed to $4.9 million in Q1 2026 per TSHA's latest filing, from $3.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $19.0 million in Q2 2022 and troughed at $1.6 million in Q1 2024.
• A 5-year average of $8.8 million and a median of $5.7 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses slumped 90.51% in 2024, then surged 365.02% in 2025.
• Over 5 years, Accumulated Expenses stood at $18.3 million in 2022, then sank by 81.04% to $3.5 million in 2023, then sank by 50.56% to $1.7 million in 2024, then soared by 109.51% to $3.6 million in 2025, then jumped by 35.09% to $4.9 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $4.9 million, $3.6 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.